Jeuveau vs. Xeomin: A Clear, Honest Comparison From a Clinic That Carries Neither

Jeuveau and Xeomin are two of the more distinctive newer-generation neurotoxins on the U.S. market. Jeuveau is marketed as “Newtox” — a 900 kDa complexed toxin from Evolus, priced 20–30% below Botox. Xeomin is the only “naked toxin” in the U.S. — a 150 kDa molecule from Merz with the accessory complexing proteins stripped out, designed to minimize long-term immunogenicity.

Both are FDA-approved for glabellar lines, both dose 1:1 against Botox, and both have meaningful clinical literature behind them. They are also genuinely different molecules — one is a complexed toxin with price-driven positioning, the other a naked toxin with an immunogenicity-driven one. This guide compares them honestly so you can take the right questions into whichever clinic you choose.

What Jeuveau and Xeomin Actually Are

Both are purified type A botulinum toxin and work by the same mechanism — blocking acetylcholine release at the neuromuscular junction so the targeted facial muscle relaxes. They differ in formulation chemistry, manufacturer, and the strategic story around each product.

• Jeuveau (prabotulinumtoxinA-xvfs) — manufactured by Evolus, FDA-approved for cosmetic glabellar lines in February 2019. It was the first U.S. neurotoxin marketed specifically for aesthetics-only use, branded as “Newtox.” It uses an approximately 900 kDa neurotoxin complex with human serum albumin; Evolus calls its purification process Hi-Pure.
• Xeomin (incobotulinumtoxinA) — manufactured by Merz Aesthetics, FDA-approved for cosmetic glabellar lines in 2011. It is the only U.S. botulinum toxin formulated as a “naked” 150 kDa molecule, with accessory proteins removed during manufacturing via the Merz XTRACT process. No accessory proteins, no albumin in the active component.

The core difference: Jeuveau carries its 150 kDa toxin inside a larger 900 kDa cluster of accessory proteins — same architectural family as Botox and Letybo. Xeomin removes that cluster entirely. Some researchers argue the accessory proteins drive long-term antibody formation in high-frequency users; the naked-toxin design lowers that risk by design. Whether this matters for the average cosmetic patient at standard doses is debated, but the chemistry is genuinely different.

Onset: How Quickly Will You See Results?

This is one of the most practically visible differences between the two.

• Jeuveau onset: Most patients see softening at 2–3 days, with peak effect at roughly 10–14 days. The EV-001/002 trials reported onset patterns similar to Dysport.
• Xeomin onset: Most patients see softening at 5–7 days, with peak around 14 days. The Sattler head-to-head study placed Xeomin’s onset closer to Botox’s window.

For an event in five days, Jeuveau’s onset is a real advantage. For routine quarterly maintenance, both are equivalent by the two-week mark.

Duration: How Long Will Results Last?

Both products are studied at the same duration window.

• Jeuveau: Median glabellar duration of 3–4 months in the EV-001/002 trials and a 40-unit phase-2 study.
• Xeomin: Median glabellar duration of 3–4 months across multiple registration trials and head-to-heads against Botox and Dysport.

Neither has shown a meaningful duration advantage. Individual factors — metabolism, muscle mass, dose, technique, treatment history — drive duration more than the brand. If duration is your top priority, discuss Daxxify, studied at a 6-month median in SAKURA.

Dosing and Unit Conversion

This is the easiest area to summarize, because both products dose identically to each other and to Botox.

Per the FDA labels:

• Jeuveau for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).
• Xeomin for glabellar lines: 20 units total, divided across 5 injection sites (4 units each).

Both follow a 1:1 ratio against Botox. If you were dosed 20 units of Botox, your injector typically uses 20 units of Jeuveau or Xeomin in the same five-point pattern. Units are not formally interchangeable on the labels, but the math is identical in routine glabellar use. This contrasts with Dysport (2.5–3:1) or Daxxify (2:1), where switching requires recalculation.

Diffusion and Precision

Both have tight diffusion profiles comparable to Botox; neither shows the broader spread pattern of Dysport. Both are well-suited for focal targets like crow’s feet, lip flips, bunny lines, and chin treatment, both behave predictably in the glabellar complex without spread into the lower frontalis, and neither requires the dilution adjustments some injectors make for broader-spread toxins. If you have done well on Botox in the past, both will feel familiar.

Cost: What You Will Actually Pay in 2026

Pricing is one of the clearer differentiators.

• Jeuveau: roughly $8–$12 per unit, generally positioned at 20–30% less than Botox per unit. A standard 20-unit glabellar treatment lands around $200–$280.
• Xeomin: roughly $10–$15 per unit. A standard 20-unit glabellar treatment lands around $200–$300.

Because both dose 1:1 against Botox, per-unit prices translate cleanly into per-treatment prices. Jeuveau tends to undercut Xeomin modestly on sticker price; both are typically less expensive than Botox at the per-unit level. Two loyalty programs to know about: Evolus Rewards for Jeuveau, which can reduce per-treatment cost if you stack multiple treatments per year; and Merz Xperience for Xeomin, useful if you also use other Merz products. Ask your clinic which programs they participate in before optimizing on sticker price alone — loyalty pricing can flip the comparison.

Side Effects and Safety

The side effect profiles are essentially identical, because the active molecule and mechanism are the same.

Most common adverse events in the registration trials for both products include headache (3–9%), injection-site reactions like mild bruising and transient swelling (1–5%), eyelid drooping under 1% in trained hands, and occasional brow asymmetry correctable with a small touch-up at the 2-week mark. Both carry the standard FDA boxed warning about the theoretical possibility of distant toxin spread; at cosmetic facial doses this has not been a clinically meaningful concern.

On long-term immunogenicity, Jeuveau carries the same baseline theoretical antibody-formation profile as other complexed type A toxins — generally low but non-zero over many years of frequent re-treatment. Xeomin’s naked-toxin formulation lowers that theoretical floor by removing accessory proteins. Clinically meaningful resistance remains rare across all type A toxins, so this is a small consideration for most cosmetic patients at standard dosing. It matters more for patients treating both cosmetic and medical indications, those re-treating very frequently, or those with prior resistance.

Who Is the Ideal Candidate for Each?

Jeuveau may be the better fit if:

• You want a name-brand Botox alternative with faster onset (2–3 days)
• You are price-sensitive and your clinic prices Jeuveau at the lower end of the range
• Your clinic participates in Evolus Rewards and you stack multiple treatments per year

Xeomin may be the better fit if:

• You specifically want the naked-toxin profile because of antibody concerns or resistance to complexed toxins
• You treat both cosmetic and medical indications and want to keep cumulative immunogenicity exposure low
• Your clinic participates in Merz Xperience and you also use other Merz products

Can You Switch Between Jeuveau and Xeomin?

Yes. Because both dose 1:1 against Botox, switching is straightforward. A few practical notes:

• Tell your new injector which product you previously had, the dose, and roughly when.
• You cannot mix the two in the same area in the same session.
• Switching from a complexed toxin to a naked toxin does not “reset” any developing antibody response; antibody risk is cumulative across all type A toxins.
• Most patients report no perceptible difference session to session, with the exception of the onset window — patients sometimes notice Jeuveau kicking in two to four days earlier than Xeomin.